|Bid||5.05 x N/A|
|Ask||5.55 x N/A|
|Day's Range||5.05 - 5.05|
|52 Week Range||3.86 - 9.60|
|Beta (5Y Monthly)||0.32|
|PE Ratio (TTM)||101.00|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for G0F.F
Grifols (MCE: GRF) (MCE:GRF.P) (NASDAQ:GRFS), a global leader in plasma-derived medicines and innovative diagnostic solutions, today announced that its AlphaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S. to screen for genetic risk of alpha1-antitrypsin deficiency (alpha-1), has been cleared by the U.S. Food and Drug Administration (FDA).
In this article, we discuss the 10 best pharma stocks to buy now. If you want to see more stocks in this selection, check out the 5 Best Pharma Stocks To Buy Now. With a compound annual growth rate (CAGR) of 9.1%, the global pharmaceuticals industry is projected to expand to $1587.1 billion in 2022 from […]
Spanish pharma group Grifols said on Friday a lawsuit filed in the United States by blood donors who claim the company violated their privacy would have no material impact, after a report in newspaper El Economista sent the shares sharply lower. The company said about 54,000 donors in Illinois had filed a lawsuit claiming Grifols breached data protection regulations, confirming the newspaper report. Grifols shares were down 5.3% on Friday morning, briefly the worst performer on the blue-chip Ibex-35 index, which was down 2.1%.